IgD型多发性骨髓瘤的研究进展

陈冲; 王雪; 王亚非

doi:10.12122/j.issn.1674-4500.2019.04.21

IgD型多发性骨髓瘤的研究进展

doi: 10.12122/j.issn.1674-4500.2019.04.21

天津医科大学肿瘤医院//国家肿瘤临床医学研究中心//天津市“肿瘤防治”重点实验室//天津市恶性肿瘤临床医学研究中心，天津 300060

基金项目: 天津市教委科研计划项目（自然科学）（2018KJ048）

详细信息

作者简介:
陈冲：陈冲，硕士，主管技师，E-mail：chongchen@tmu.edu.cn

通讯作者:
王亚非，博士，副主任医师，E-mail：drwang2005@163.com

计量
- 文章访问数: 975
- HTML全文浏览量: 361
- PDF下载量: 19
- 被引次数: 0
出版历程
- 收稿日期: 2019-08-14
- 刊出日期: 2019-12-01

Progress in research on IgD multiple myeloma

Cancer Institute and Hospital, Tianjin Medical University/National Clinical Research Center for Cancer/Key Laboratory of Cancer Prevention and Therapy, Tianjin/Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China

摘要

摘要: 多发性骨髓瘤起源于浆细胞，是一种分泌单克隆免疫球蛋白或轻链（M蛋白）从而导致相关器官或组织损伤的恶性肿瘤。IgD型多发性骨髓瘤是极少见的一种骨髓瘤类型，目前根据国外报道IgD型MM约占所有类型骨髓瘤的2%，国内报道发生率则为4%~8%，预后相对较差。关于IgD型MM的临床特点、治疗以及生存情况等国内尚无大样本的研究。故本文是针对IgD型多发性骨髓瘤患者的临床特点、治疗疗效、生存及预后进行综述，目的是加强对该类型多发性骨髓瘤生物学特性的认识，帮助临床医生在疾病诊疗过程中做出正确的决策及个体化治疗，从而提高患者预后。
- IgD型多发性骨髓瘤 /
- 临床特点 /
- 治疗疗效 /
- 预后
Abstract: Multiple myeloma (MM) is a malignant tumor originating from plasma cells, secreting monoclonal immunoglobulin or monoclonal protein, causing damage to related organs or tissues. IgD type is a rare type of myeloma, which accounts for about 2%, and the reported rate is about 4% to 8% in China, and the prognosis is poor. Regarding the clinical characteristics and survival of IgD type MM, there is no large-scale study in China. This article reviews the clinical features, therapeutic efficacy, survival and prognosis of patients with IgD type MM. It aims to enhance our understanding of the biological characteristics of this type of MM, and help clinicians make correct diagnosis and treatment decisions and further improve the prognosis of such patients.
- IgD type MM /
- clinical features /
- treatment efficacy /
- prognosis

HTML全文

参考文献(35)

[1]	Chen L, Fan F, Deng J, et al. Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era[J]. Ann Hematol, 2019, 98(4): 963-70. doi: 10.1007/s00277-018-3582-4
[2]	Radocha J, Hájek R, Brožová L, et al. Simplified novel prognostic score for real-life older adults with multiple myeloma-registry-based analysis[J]. Ann Hematol, 2019, 98(4): 951-62. doi: 10.1007/s00277-018-3568-2
[3]	Wang JH, Jiang FM, Liu BX, et al. Immunophenotypic analysis of IgD multiple myeloma with loss of light chain expression[J]. J China Med Univ, 2018, 47(7): 56-62.
[4]	Wang W, Zhang CX, Li ZL, et al. Detection of intracellular IgD using flow cytometry could be a novel and supplementary method to diagnose IgD multiple myeloma[J]. BMC Cancer, 2018, 18(1): 650-62. doi: 10.1186/s12885-018-4562-8
[5]	Biaz A, Uwingabiye J, Rachid A, et al. Interpretation difficulties of serum immunofixation test in immunoglobulin D multiple myeloma with hidden lambda light chains[J]. Clin Lab, 2018, 64(6): 1065-9.
[6]	Abramson HN. Monoclonal antibodies for the treatment of multiple myeloma: an update[J]. Int J Mol Sci, 2018, 19(12): 3924-38. doi: 10.3390/ijms19123924
[7]	Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment[J]. Am Fam Physician, 2017, 95(6): 373-83.
[8]	胡从华, 胡斌, 苏梦雅, 等. 以血小板减少为首发表现的IgD多发性骨髓瘤1例报告[J]. 中国临床医学, 2018, 25(6): 1038-40. doi: 10.12025/j.issn.1008-6358.2018.20180432
[9]	Chen J, Fang M, Chen X, et al. N-glycosylation of serum proteins for the assessment of patients with IgD multiple myeloma[J]. BMC Cancer, 2017, 17(1): 881-91. doi: 10.1186/s12885-017-3891-3
[10]	Chen K, Cerutti A. New insights into the enigma of immunoglobulin D[J]. Immunol Rev, 2010, 237(1): 160-79. doi: 10.1111/j.1600-065X.2010.00929.x
[11]	Rowe DS, Fahey. A New Class Of Human Immunoglobulins normal serum IgD[J]. J ExpMed, 1965, 121(3): 185-99.
[12]	Martin T, Huff CA. Multiple myeloma: current advances and future directions[J]. Clin Lymphoma Myeloma Leuk, 2019, 19(5): 255-63. doi: 10.1016/j.clml.2019.03.025
[13]	Shimamoto Y, Anami Y, Yamaguchi M. A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients[J]. Eur J Haematol, 1991, 47(4): 262-7.
[14]	Morris C, Drake M, Apperley J, et al. Efficacy and outcome of autologous transplantation in rare myelomas[J]. Haematologica, 2010, 95(12): 2126-33. doi: 10.3324/haematol.2010.022848
[15]	安然, 何海燕, 姜华, 等. 130例IgD型多发性骨髓瘤临床特点及预后分析[J]. 临床血液学杂志, 2017, 30(2): 194-7.
[16]	Kim MK, Suh C, Lee DH, et al. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients[J]. Ann Oncol, 2011, 22(2): 411-6. doi: 10.1093/annonc/mdq393
[17]	Wang GR, Sun WJ, Chen WM, et al. Immunoglobulin D multiple myeloma: disease profile, therapeutic response, and survival[J]. Acta Haematol, 2016, 136(3): 140-6. doi: 10.1159/000446599
[18]	李昱瑛, 刘晓亮, 高素君, 等. IgD型多发性骨髓瘤27例临床分析[J]. 中华血液学杂志, 2017, 38(10): 893-5. doi: 10.3760/cma.j.issn.0253-2727.2017.10.014
[19]	Wang L, Zhang YZ. Research progress on multiple myeloma with extramedullary disease[J]. J Exp Hematol, 2016, 24(3): 945-8.
[20]	Natori K, Izumi H, Nagase D, et al. IgD myeloma indicated by plasma cells in the peripheral blood and massive pleural effusion[J]. Ann Hematol, 2008, 87(7): 587-9. doi: 10.1007/s00277-008-0444-5
[21]	Bladé J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases[J]. J Clin Oncol, 1994, 12(11): 2398-404. doi: 10.1200/JCO.1994.12.11.2398
[22]	张磊, 刘会兰, 郑昌成, 等. 17例IgD型多发性骨髓瘤临床分析[J]. 临床血液学杂志, 2015, 28(1): 12-5, 18.
[23]	杨璐, 徐俊荣, 顾兵. 免疫固定电泳技术对多发性骨髓瘤的分型诊断及预后判断价值[J]. 检验医学与临床, 2011, 8(16): 1975-6. doi: 10.3969/j.issn.1672-9455.2011.16.030
[24]	Nair B, Waheed S, Szymonifka J, et al. Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols[J]. Br J Haematol, 2009, 145(1): 134-7. doi: 10.1111/j.1365-2141.2008.07547.x
[25]	Wang W, Yan YG, Zhang LF, et al. Analysis on laboratory results of IgD type multiple myeloma[J]. J Clin Hematol, 2015, 28(1): 16-8.
[26]	Inchiappa L, Herbaux C, Guidez S, et al. Prognostic of IgD myeloma in the era of novel agents[J]. Blood, 2013, 122(21): 1880-9. doi: 10.1182/blood.V122.21.1880.1880
[27]	Zagouri F, Kastritis E, Symeonidis AS, et al. Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents[J]. Eur J Haematol, 2014, 92(4): 308-12. doi: 10.1111/ejh.12255
[28]	Selene Ⅱ, Jose JA, Khalil MJ, et al. Presentation patterns, diagnostic markers, management strategies, and outcomes of IgD multiple myeloma: a systematic review of literature[J]. Cureus, 2019, 11(2): e4011-21.
[29]	Kang J, Hong JY, Yoon DH, et al. Efficacy and survival outcome associated with the use of novel agents and autologous stem cell transplantation in cases of immunoglobulin D multiple myeloma in Korea[J]. Acta Haematol, 2018, 139(3): 185-92. doi: 10.1159/000486664
[30]	Wang XJ, Yin LF. Diagnosis experience and treatment of 10 cases of IgD mutiple myeloma[J]. China Contin Med Educat, 2017, 9(8): 144-6.
[31]	Sharma A, Binazir T, Sintow A, et al. An extremely rare manifestation of multiple myeloma: an immunoglobulin D secreting testicular plasmacytoma[J]. Cureus, 2017, 9(6): e1400-9.
[32]	Chong YP, Kim S, Ko OB, et al. Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience[J]. J Korean Med Sci, 2008, 23(5): 819-24. doi: 10.3346/jkms.2008.23.5.819
[33]	Reece DE, Vesole DH, Shrestha S, et al. Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study[J]. Clin Lymphoma Myeloma Leuk, 2010, 10(6): 458-63. doi: 10.3816/CLML.2010.n.078
[34]	Liu Y, Ke XY, Wang J, et al. Clinical characteristics and therapeutic efficacy of immunoglobin D multiple myeloma[J]. J Exp Hematol, 2014, 22(6): 1628-32.
[35]	Mcglynn F, Glavey S, Sargent J, et al. IgD myeloma: dialysis-independence following high-dose melphalan and autologous stem cell transplantation[J]. Acta Haematol, 2018, 140(3): 176-7. doi: 10.1159/000493118